Flavie Coquel, Sing-Zong Ho, Keng-Chang Tsai, Chun-Yen Yang, Antoine Aze, Julie Devin, Ting-Hsiang Chang, Marie Kong-Hap, Audrey Bioteau, Jerome Moreaux, Domenico Maiorano, Philippe Pourquier, Wen-Chin Yang, Yea-Lih Lin, Philippe Pasero
{"title":"Synergistic effect of inhibiting CHK2 and DNA replication on cancer cell growth.","authors":"Flavie Coquel, Sing-Zong Ho, Keng-Chang Tsai, Chun-Yen Yang, Antoine Aze, Julie Devin, Ting-Hsiang Chang, Marie Kong-Hap, Audrey Bioteau, Jerome Moreaux, Domenico Maiorano, Philippe Pourquier, Wen-Chin Yang, Yea-Lih Lin, Philippe Pasero","doi":"10.7554/eLife.104718","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer cells display high levels of oncogene-induced replication stress (RS) and rely on DNA damage checkpoint for viability. This feature is exploited by cancer therapies to either increase RS to unbearable levels or inhibit checkpoint kinases involved in the DNA damage response. Thus far, treatments that combine these two strategies have shown promise but also have severe adverse effects. To identify novel, better-tolerated anticancer combinations, we screened a collection of plant extracts and found two natural compounds from the plant, <i>Psoralea corylifolia</i>, that synergistically inhibit cancer cell proliferation. Bakuchiol inhibited DNA replication and activated the checkpoint kinase CHK1 by targeting DNA polymerases. Isobavachalcone interfered with DNA double-strand break repair by inhibiting the checkpoint kinase CHK2 and DNA end resection. The combination of bakuchiol and isobavachalcone synergistically inhibited cancer cell proliferation in vitro. Importantly, it also prevented tumor development in xenografted NOD/SCID mice. The synergistic effect of inhibiting DNA replication and CHK2 signaling identifies a vulnerability of cancer cells that might be exploited by using clinically approved inhibitors in novel combination therapies.</p>","PeriodicalId":11640,"journal":{"name":"eLife","volume":"13 ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"eLife","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.7554/eLife.104718","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer cells display high levels of oncogene-induced replication stress (RS) and rely on DNA damage checkpoint for viability. This feature is exploited by cancer therapies to either increase RS to unbearable levels or inhibit checkpoint kinases involved in the DNA damage response. Thus far, treatments that combine these two strategies have shown promise but also have severe adverse effects. To identify novel, better-tolerated anticancer combinations, we screened a collection of plant extracts and found two natural compounds from the plant, Psoralea corylifolia, that synergistically inhibit cancer cell proliferation. Bakuchiol inhibited DNA replication and activated the checkpoint kinase CHK1 by targeting DNA polymerases. Isobavachalcone interfered with DNA double-strand break repair by inhibiting the checkpoint kinase CHK2 and DNA end resection. The combination of bakuchiol and isobavachalcone synergistically inhibited cancer cell proliferation in vitro. Importantly, it also prevented tumor development in xenografted NOD/SCID mice. The synergistic effect of inhibiting DNA replication and CHK2 signaling identifies a vulnerability of cancer cells that might be exploited by using clinically approved inhibitors in novel combination therapies.
期刊介绍:
eLife is a distinguished, not-for-profit, peer-reviewed open access scientific journal that specializes in the fields of biomedical and life sciences. eLife is known for its selective publication process, which includes a variety of article types such as:
Research Articles: Detailed reports of original research findings.
Short Reports: Concise presentations of significant findings that do not warrant a full-length research article.
Tools and Resources: Descriptions of new tools, technologies, or resources that facilitate scientific research.
Research Advances: Brief reports on significant scientific advancements that have immediate implications for the field.
Scientific Correspondence: Short communications that comment on or provide additional information related to published articles.
Review Articles: Comprehensive overviews of a specific topic or field within the life sciences.